Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Affiliations

• ¹ Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ² Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
• ³ The Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
• ⁴ Department of Laboratory Medicine and Pathology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
• ⁵ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁶ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁷ Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁸ Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁹ Kura Oncology, San Diego, CA, USA.
• ¹⁰ Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. cpratil1@jhmi.edu.
• ¹¹ Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. cpratil1@jhmi.edu.